Globally, more than 55 million people suffer from Alzheimer’s disease (AD) or other dementias, and current diagnosis methods are challenging, invasive and expensive.
Blood-based biomarkers provide a more efficient alternative, with decreased invasiveness, cost and time. iLoF’s optical fingerprints of biofluids, offers a solution to develop a differential AD screening tool and a predictive model for dementia progression. A 1500 individuals multicentric study is ongoing to validate this agnostic platform, expected to transform AD screening and dementia-related diseases.
Partners
